Positioning no disclosures inside 60 days, left as found
Options put/call open interest 0.18, read 2026-11-03
Ethical does not pass the values gate
Price34.04 USD
Fair value41.28
Ethical score30.0/100
Value readUndervaluedas of 6 Nov 2026
Our investment reviews on this name
2026-11-05Read Markup35.52-4.2% to today Markdown gives way to Markup after a 13% slide in 10 weeks
2026-08-27Read Markdown40.70-16.4% to today ✓Markup gives way to Markdown after a 16% slide in 8 weeks
2026-07-02Read Markup48.53-29.9% to today First review on file: Markup
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Leonardo DRS Inc holds its Distribution at $34.04. Elevated stress, defensive posture warranted, held for 1 days.
As held on the ledger · 2026-11-06
Phase
Distribution · caution
Quantitative state
Elevated stress, defensive posture warranted, held for 1 days
Price at the screen
$34.04
Valuation
31.66 trailing · 25.49 forward price to earnings
Values screen
FAIL· score 30.0
The Workings
Five Screens, Shown in Full
Does not pass. Excluded industry: Aerospace & Defense
Test
Figure
Limit
What it means
Status
Business activity
Excluded
Core business clean
Excluded industry: Aerospace & Defense
Fail
Debt load
Excluded
Below 33%
Interest-bearing debt is of its assets, above the one-third ceiling the screen allows.
Fail
Interest-bearing cash
Excluded
Below 33%
Interest-bearing cash and securities are of assets, above the one-third limit.
Fail
Receivables
Excluded
Below 49%
Money owed to the company is of assets, above the 49% limit.
Fail
Revenue purity
Excluded
Below 5%
of revenue comes from non-compliant sources, over the 5% line.
Fail
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Falls Short, in Plain English
Leonardo DRS does not clear the screen at the business-activity stage. It operates in aerospace and defense, so the financial ratios are not the deciding factor here.
Read as at 2026-11-07. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when DRS's ethical verdict changes
Today DRS does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
The quantitative screen above is arithmetic. Separately, community boycott lists cite this company: Documented on AFSC Investigate. The desk records that flag here without folding it into the verdict: the screen measures the balance sheet, the overlay informs the conscience, and they are different judgements that belong to different owners. The second one is yours.
What the Numbers Say It Is Worth
The Fair Value Range
Our analysis reads Undervalued vs our fair value, as of 6 Nov 2026: it trades at roughly an 18% discount to our $41.28 fair value, narrow competitive moat, 11.00% revenue growth.
Fair value range in USD, drawn from the 2026-11-06 screen. The gold marker is the market price at the same screen. A 17.5% discount to the base estimate.
Where our models see it going: fair-value estimate $41.28, with a range of $39.60 to $47.47, dated to the 2026-11-06 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Defence name blocked by ethical screen
Military sensors and computing systems keep defence platforms running, yet the sector itself triggers an automatic ethical fail. We pass on Leonardo DRS before any valuation debate begins.
Revenue grows at just 6 percent, margins sit at 8 percent and return on equity reaches only 11 percent. Shares trade at 30.7 times forward earnings against a fair value that already sits below the current price, so the numbers offer no comfort either.
A narrow moat and heavy reliance on government budgets add further cyclical risk, even if analysts push a higher target. The ethical block remains decisive. Analysis, not advice.
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The main risks here are ordinary market swings and the chance our fair-value read proves too optimistic.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
DRS trades on NASDAQ. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-11-05Markup · changed$35.52+2.9%Entry 17
The framework has shifted from markdown to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 2.9% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading bearish. Over the past year the shares are up 8%. Our forward projection puts the odds of a 10% gain over the next month near 32%. The street (10 analysts) rates it none, with a mean price target of $53. Insiders have been net sellers over the past quarter. Since the last review it its composite score eased.
2026-10-29Markdown$34.51-2.6%Entry 16
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 2.6% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is momentum reading bearish. Over the past year the shares are up 8%. Our forward projection puts the odds of a 10% gain over the next month near 32%. The street (10 analysts) rates it none, with a mean price target of $53. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-28Markdown$35.42+0.0%Entry 15
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is momentum reading bearish. Over the past year the shares are up 8%. Our forward projection puts the odds of a 10% gain over the next month near 32%. The street (10 analysts) rates it none, with a mean price target of $53. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-27Markdown$35.42+0.0%Entry 14
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is momentum reading bearish. Over the past year the shares are up 8%. Our forward projection puts the odds of a 10% gain over the next month near 32%. The street (10 analysts) rates it none, with a mean price target of $53. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-26Markdown$35.42+0.0%Entry 13
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is momentum reading bearish. Over the past year the shares are up 8%. Our forward projection puts the odds of a 10% gain over the next month near 32%. The street (10 analysts) rates it none, with a mean price target of $53. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-25Markdown$35.42+0.0%Entry 12
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading bearish. Over the past year the shares are up 8%. Our forward projection puts the odds of a 10% gain over the next month near 32%. The street (10 analysts) rates it none, with a mean price target of $53. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-24Markdown$35.42+0.0%Entry 11
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading bearish. Over the past year the shares are up 8%. Our forward projection puts the odds of a 10% gain over the next month near 32%. The street (10 analysts) rates it none, with a mean price target of $53. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-23Markdown$35.42+0.0%Entry 10
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading bearish. Over the past year the shares are up 8%. Our forward projection puts the odds of a 10% gain over the next month near 32%. The street (10 analysts) rates it none, with a mean price target of $53. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-22Markdown$35.42+0.0%Entry 9
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading bearish. Over the past year the shares are up 8%. Our forward projection puts the odds of a 10% gain over the next month near 32%. The street (10 analysts) rates it none, with a mean price target of $53. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-21Markdown$35.42-2.3%Entry 8
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 2.3% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading bearish. Over the past year the shares are up 8%. Our forward projection puts the odds of a 10% gain over the next month near 32%. The street (10 analysts) rates it none, with a mean price target of $53.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
